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Hepatitis C virus (HCV) is a progressive disease that may result in Chronic active hepatitis,
cirrhosis, and hepatocellular carcinoma. Cytokeratin(CK)18 is an intermediary filament
protein, expressed in hepatocytes, which is proteolytically cleaved during liver damage.
M30 epitope of cytokeratin18(CK18-M30) is involved at different levels in apoptotic path-
ways. The aim of this study to investigate the diagnostic accuracy of cytokeratin
18-apoptosin M30 fragments (CK18-M30) as non-invasive method of liver fibrosis assess-
ment and their correlation to METAVIR score. Serum concentrations of CK18-M30 were
measured by ELISA in One hundred and sixty eight chronic hepatitis C patients (112 males
and 56 females). Results showed that serum concentrations of CK18 were significantly
increased in a stepwise fashion from A0 to A3 and from F0 to F4.There was highly signif-
icant positive correlation between CK18 and fibrosis stages (r ¼ 0.881 & p < 0.001) and
activity grades (r ¼ 0.881 & p < 0.001). Also, serum CK18 correlated positively with serum
levels of transaminases (r ¼ 0.355 & p < 0.05). CK18 was correlated positively with viral level
(r ¼ 0.3 & p < 0.05). It was concluded that Elevated serum CK18-M30, as an indicator of
enhanced apoptosis of hepatocytes, was increased and correlated significantly with
inflammation severity, stages of fibrosis, transaminases (ALT) levels and viral load in
chronic HCV patients. These findings may place CK18-M30 as a non-invasive marker of
liver fibrosis and disease activity.
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Hepatitis C virus (HCV) is a progressive disease thatmay result
in chronic active hepatitis, cirrhosis and hepatocellular car-
cinoma. It is estimated nationally that over 200 million people
are infected and about 80% progress into chronic form [20].
Egypt has the highest prevalence of hepatitis C virus (HCV) in
the world, estimated nationally at 14.7% [15].
Cytokeratin (CK18) is major intermediate filament protein
in liver cells. It is expressed in hepatocytes by both apoptosis
and necrosis which are the triggering for the inflammatory
condition, regeneration and liver fibrosis [1].
The apoptotic pathway is composed of two arms, intrinsic
and extrinsic one. In the final common step of apoptosis, CK18
which is expressed by hepatocytes is cleaved resulting in
exposure of its M30 fragment and because of the liver is highly
perfused organ, it accumulates very rapidly in the circulation
of patients with chronic liver disease including HCV infection
[5,23].
Human Apoptosense M30 is an ELISA based monoclonal
antibody [13]. This antibody specifically binds to the cleaved
CK18 fragments but not to the uncleaved fragments providing
a non invasive, simple and quantitative test for hepatocyte
death [8,11].
Liver biopsy is the gold standard method for diagnosis,
assessment of severity of liver injury as well as monitoring of
therapy although, it has many complications [7]. So, the
presence of non invasive, simple and low cost test is highly
needed [9].
Serum Cytokeratin 18-Apoptosense M30 would define the
apoptotic process [23]and by finding its correlation with the
severity of inflammation, staging of fibrosis it would replace
liver biopsy making it unnecessary in many instances
providing serum biomarker for diagnosis of liver injury and
treatment monitoring.
Aim of this study was to assess the levels of Caspase-
cleaved fragments of CK-18 in the sera of patients with
chronic HCV infection and evaluate its correlation with he-
patocyte apoptosis and any correlations with stages of fibrosis
and grades of inflammation.2. Patients
The study involved 168 patients with chronic hepatitis C
recruited from Tropical Medicine department, Mansoura
University Hospitals during the period from January 2013 to
January 2014 (112 male and 56 female) with age ranged be-
tween 23 and 56 years. An informed consent was obtained
from all patients included in the study.3. Methods
3.1. Routine laboratory investigations
The following investigations were done CBC, Liver function
tests, Prothrombin time, INR, Blood sugar test, Renal function
tests, Autoimmune profile and lipid profile.3.2. Chronic HCV diagnosis
Diagnosis of chronic hepatitis C based on presence of anti-
HCV antibodies, using third-generation assays (Axysm HCV
EIA test system), quantitative HCV RNA by reverse transcrip-
tase (Stratagene Mx3000P Real-Time PCR System with a
detection limit of 15 IU/ml) and liver biopsy showing chronic
hepatitis.
3.3. Abdominal ultrasound
Abdominal US was done to study size, pattern of liver, spleen,
presence or absence of ascites and exclusion of hepatocellular
carcinoma.
3.4. Ultrasound guided liver biopsy and histological
assessment
All patients had ultrasound guided liver biopsy showing
chronic hepatitis. For percutaneous approaches the patient
lies supine. The borders of the liver are usually defined by
percussion or visualised by ultrasound. In most instances the
intercostal space in the mid-axillary line just cephalad to the
costal margin is then infiltrated with local anaesthetic, and a
small incision is made through the dermis. The biopsy needle
is then advanced into the intercostal space. The patient then
holds their breath in expiration. The subsequent procedure for
taking the biopsy according to APASL recommendation for
liver biopsy (2009). Liver histology was graded and staged ac-
cording to METAVIR fibrosis scaling system that classifies
fibrosis into five stages (F0eF4) and activity into four grades
(A0eA3) [16].
3.5. Blood sampling
Blood samples were obtained from all subjects at the same
setting of liver biopsy. Serum alanine aminotransferase (ALT),
serum aspartate amino-trans-ferase (AST) were determined
by Hitachi 902 instrument and HBs Ag for HBV was also done.
3.6. Assessment of Cytokeratin-18 Apoptosense M30
levels
Serum human Apoptosense M30 was assessed by ELISA sup-
plied by Glory Sience co., Ltd (USA). A solid phase microwell
coated by purified human Apoptosense M30 Antibody and
horse reddish peroxidase (HRP) labelled with anti Apopto-
sense M30 was added forming Ab-(Ag eab enzyme complex),
washing the microwells and adding substrate tetramethyl
benzidine (TMB) which is proportional to M30 concentration
in the sample giving a blue colour which turned yellow after
stopping reaction with sulphuric acid solution and the plate
was read by spectrophotometry at a wave length 450 nm and
results are interpolated from Apoptosense M30 standard
curve [5].
3.7. Statistical analysis
Data was computed with the statistical package for the social
science, windows 7 versions, USA (SPSS17 software). Variable
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these variables, the T test was applied for group differences.
Non parametric data were expressed as median. The Kalmo-
goroveeSmirnov test was check normal distribution of data.
For correlation analysis, spearman's correlation coefficients
were calculated with two-tailed P value. Value of P < 0.05 was
considered significant [14].4. Results
Demographic data of the studied group according to stages of
fibrosis are presented in (Table 1). As found there were 26
(15.5%) patients had fibrosis stage 0, 40 (23.8%) patients had
fibrosis stage1, 40 (23.8%) patients had fibrosis stage 2, 36
(21.4%) patients had fibrosis stage 3 and 26 (15.5%) patients
had fibrosis stage 4.
By studying correlation between CK18 and parameters
including stages of fibrosis, grades of inflammation (activity),
ALT levels and viral load as illustrated in (Table 2). There was
highly significant positive correlation between CK-18 and
fibrosis stages (r ¼ 0.881 & p  0.001). Also, a highly positive
correlationwas obtained between CK-18 and activity (r¼ 0.881
& p  0.001). On the other hand, when comparing CK-18 and
ALT levels a significant positive correlation was obtained
(r ¼ 0.355 & p < 0.05). Also, when comparing CK-18 with viral
load, a significant positive correlation was obtained (r ¼ 0.3 &
p < 0.05).
A significant correlation between CK18 levels and stages of
fibrosis illustrated in (Fig. 2). Also, A significant correlation
between CK18 levels and grades of inflammation (activity)
illustrated in (Fig. 3). And as illustrated in (Figs. 4 and 5), CK18-
M30 correlated positively with serum levels of liver enzyme
(ALT) and viral load respectively.
Comparison between patients according to stages of
fibrosis and CK-18 levels was done using one way ANOVA testTable 1 e Demographic data according to stages of
fibrosis of the studied groups.
No Ageyyears Gender
Mean ± SD Minimum Maximum Male Female
F0 26 30.88 ± 5.29 23 40 18 8
F1 40 44.65 ± 6.39 34 56 30 10
F2 40 43.37 ± 3.27 39 49 28 12
F3 36 45.02 ± 1.82 42 48 18 18
F4 26 49.40 ± 0.99 48 51 18 8
Table 2 e Correlation between CK-18 levels and other
parameters.
Correlation pair Correlation coefficient (r) P value
CK-18 & Fibrosis 0.881 0.001
K-18 & activity 0.844 0.001
CK-18 & viral level 0.300 0.05
CK-18 & Liver enzyme 0.355 0.05and there was highly significant decreased CK-18 levels in
stage F0 compared to stage F1 (p  0.001). Also, there was
highly significant decreased CK-18 levels in stage F0 compared
to stage F2 group (p 0.001). And, CK-18 in stage F0 was highly
significant decreased as compared to stage F3 (p < 0.001). Also,
There was highly significant decreased in stage F0 CK-18
levels as compared to these levels of stage F4 (p  0.001)
respectively (Table 3).
A highly significant decreased in stage F1 CK-18 levels as
compared to these levels of stage F2 (p  0.001). And, CK-18
levels was highly significantly decreased in stage F1 as
compared to stage F3 (p  0.001). Also, highly significant
decreased in stage F1 CK-18 levels was found as compared to
stage F4 (p  0.001). However, CK-18 levels in stage F2 was
significantly decreased as compared to stage F3 and stage F4
(p  0.001 and p  0.001) respectively. CK-18 levels in stage F3
was highly significant decreased as compared to stage F4
(p 0.001) (Table 3) and the serum concentration of CK18- was
significantly increased in a stepwise fashion from F0 to F4 as
illustrated in (Fig. 1).5. Discussion
The study showed a significantly higher level of CK18 in the
serum of patients with marked fibrosis compared to patients
with lower levels of fibrosis. These results are in agreement
with those of Akl et al., who reported that CK18 expression
was found to be increased in chronic HCV cases with higher
stages of fibrosis that were progressing into cirrhosis, espe-
cially at METAVIR stage F4 [2,3].
The serum CK18 levels were significantly increased in a
stepwise fashion from A0 to A3 as this result indicated that
serum CK18 levels correlated with grades of inflammation.
These data support a central role for apoptosis in disease
pathogenesis, and this finding was similar to the results re-
ported by many studies [12,16,18,19].
Increased CK18 expression within hepatocytes was re-
ported in higher grades of chronic inflammation compared to
lower grades by Valva et al. and this indicates that the rate of
hepatocyte apoptosis was correlated with the severity of
inflammation and was increased in cases of severe hepatitis C
[10,12,21].
This study found that serum CK18 levels were strongly
correlated with ALT levels. However, chronic hepatitis C pa-
tients with normal ALT levels had lower levels of CK18 than
those with elevated ALT levels.
This result may be important for patients with normal
aminotransferase levels. Therefore, apoptotic CK18 in the
serum of patients with chronic hepatitis C are associated with
higher ALT level and histological liver damage. This agree
with many studies that found elevated serum apoptotic CK18
levels in patients with chronic hepatitis with high ALT levels
[18,22].
Our analysis of hepatitis C viraemia by quantitative PCR
showed significant difference in viral load relative to serum
CK18 levels. This finding was inconsistent with data from
Asselah and Biechewho found that apoptosis did not correlate
With HCV load [1,4].
Fig. 1 e Comparison between patients according to stages of fibrosis and CK18 levels.
Fig. 2 e Correlation between CK18 levels and stages of fibrosis.
Fig. 3 e Correlation between CK18 levels and grades of inflammation (activity).
e g y p t i a n j o u rn a l o f b a s i c a n d a p p l i e d s c i e n c e s 2 ( 2 0 1 5 ) 1 5 3e1 5 8156
Fig. 4 e Correlation of CK18 levels and liver enzyme (ALT) levels.
Fig. 5 e Correlation between CK18 levels and viral load.
Table 3 e Comparison between patients according to
stages of fibrosis and CK-18 levels.
Fibrosis stage CK18 range Mean ± SD p
Minimum Maximum
F0 (26) 2.80 20.10 14.59 ± 4.52 0.001
F1(40) 12.20 32.10 26.25 ± 4.52
F2(40) 23.10 39.80 31.45 ± 4.31
F3(36) 20.50 43.60 35.62 ± 5.83
F4(26) 40.00 52.00 45.70 ± 3.31
e g y p t i a n j o u rn a l o f b a s i c a n d a p p l i e d s c i e n c e s 2 ( 2 0 1 5 ) 1 5 3e1 5 8 1576. Conclusion
Elevated serum CK18-M30, as an indicator of enhanced
apoptosis of hepatocytes, was significantly increased and
correlated significantly with inflammation severity, stages of
fibrosis, transaminases levels and viral load in chronic HCV
patients. These findings may place CK18-M30 as a non-
invasive marker of liver fibrosis and disease activity.
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